Humanin antagonists: Mutants that interfere with dimerization inhibit neuroprotection by Humanin

Yuichi Hashimoto, Kenzo Terashita, Takako Niikura, Yohichi Yamagishi, Miho Ishizaka, Kohsuke Kanekura, Tomohiro Chiba, Marina Yamada, Yoshiko Kita, Sadakazu Aiso, Masaaki Matsuoka, Ikuo Nishimoto

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


The 24-residue peptide Humanin (HN) protects neuronal cells from insults of various Alzheimer's disease (AD) genes and Aβ by forming a homodimer. We have previously shown that P3A, S7A, C8A, L9A, L12A, T13A, S14A and P19A mutations nullify the neuroprotective function of HN [Yamagishi, Y, Hashimoto, Y., Niikura, T. & Nishimoto, I. (2003) Peptides, 24, 585-595]. Here we examined whether any of these 'null' mutants could function as dominant-negative mutants. Homodimerization-defective mutants, P3A-, L12A-, S14A- and P19A-HN, specifically blocked neuroprotection by HN, but not by activity-dependent neurotrophic factor. Furthermore, insertion of S7A, the mutation that blocks the homodimerization of HN, but not insertion of G5A abolished the antagonizing function of L12A-HN. While L12A-HN and G5A/L12A-HN actually inhibited HN homodimerization, S7A/L12A-HN had no effect. These data indicate that P3A-, L12A-, S14A- and P19A-HN function as HN antagonists by forming an inactive dimer with HN. This study provides a novel insight into the understanding of the in vivo function of HN, as well as into the development of clinically applicable HN neutralizers.

Original languageEnglish
Pages (from-to)2356-2364
Number of pages9
JournalEuropean Journal of Neuroscience
Issue number9
Publication statusPublished - 2004 May


  • Alzheimer's disease
  • Dimerization
  • Neuronal death
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Humanin antagonists: Mutants that interfere with dimerization inhibit neuroprotection by Humanin'. Together they form a unique fingerprint.

Cite this